Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 20/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150474 | 0.90 | GPBAR1 (0.63) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2217335 | 0.89 | GPBAR1 (0.76) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL16649355 | 0.86 | GPBAR1 (0.60) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3142921 | 0.85 | GPBAR1 (0.59) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3142750 | 0.82 | GPBAR1 (0.74) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3142383 | 0.82 | GPBAR1 (0.65) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3145125 | 0.81 | GPBAR1 (0.64) | GPBAR1CYP3A4CYP2C9 | |
| SCHEMBL3146348 | 0.81 | GPBAR1 (0.70) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3141314 | 0.81 | GPBAR1 (0.60) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3141311 | 0.81 | GPBAR1 (0.66) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011089099-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-28 | — | — | WO | claimed |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-07-21 | — | — | US | claimed |
| EP-2526096-B1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8729091-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729091-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8420647-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420647-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2011089099-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011089099-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | P2RY1, GPBAR1, ADORA1 | GPBAR1 2/4885CYP3A4 1133/4885CYP2C9 1407/4885 |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | P2RY1, GPBAR1, ADORA1 | GPBAR1 2/4885CYP3A4 1133/4885CYP2C9 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.